How inflammation resolution may support a better sleep recovery?

Ambiotis is very proud to share this great publication resulting from a solid collaborative work between Israel Deaconess Medical Center, the Harvard Medical School and Ambiotis !

This new scientific publication is entitled :“Greater NREM Sleep Rebound in Response to Experimental Sleep Disturbance Associated with Higher Inflammatory Resolution in Humans”.  These data suggest that during recovery from sleep disturbance, NREM (non-rapid eye movement) sleep promotes inflammatory resolution, thereby acting as the sleep state that protects against low-grade systemic inflammation, which has been frequently observed as a consequence of sleep disturbances.

More information on this article: 

Check the publication here :“Greater NREM Sleep Rebound in Response to Experimental Sleep Disturbance Associated with Higher Inflammatory Resolution in Humans”. 

More information

Ambiotis is very proud to have actively participated with OSE Immunotherapeutics to the development of an antibody that targets resolution of inflammation pathways. ChemR23 is a GPCR targeted by Resolvin E1. OSE-230 is an anti-ChemR23 agonist antibody that have been shown to promote efferocytosis (clearance of dead cells by macrophages) and reduce apoptosis of neutrophils; major hallmarks of inflammation resolution. It also triggered resolution in chronic colitis model with beneficial impact on tissue lesions, fibrosis and inflammation-driven tumors. This is a first-in-class drug dealing with pro-resolutive properties.

Check the publication here :“Agonist anti-ChemR23 mAb reduces tissue neutrophil accumulation and triggers chronic inflammation”. 

More information

PCTR1 : a new biomarker for host defense and tissue repair 

How do tissues fight against infection and regenerate?

Resolution of inflammation is a natural biological process that  facilitates host defense and promotes tissue repair. It is already known that this process is governed by specialized pro-resolving mediators (SPM). 

In this recent publication, Sansbury et al. described the beneficial properties of a novel series cysteinyl-SPM (cys-SPM) that stimulate tissue regeneration.They screened nine structurally distinct cys-SPMs and they found that PCTR1 uniquely enhanced human keratinocyte migration, reduced wound bacteria levels and decreased inflammatory monocytes/macrophages.
Overall, PCTR1 is involved in host defense and tissue repair. 

These results suggest that PCTR1 could inform new approaches for therapeutic management of delayed tissue repair and infection.

More information about this article entitled "PCTR1 Enhances Repair and Bacterial Clearance in Skin Wounds" : click here

More information